These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38907678)

  • 1. Study Protocol for Pain Self-Management and Patient-Oriented Buprenorphine Dosing for Pain and Retention in Office-Based Opioid Treatment: A Hybrid Type 1, 2 × 2 Factorial Randomized Controlled Trial.
    Salay M; Edwards KA; Winstanley EL; Bachrach RL; Bulls HW; Hanmer J; Liebschutz JM; Robbins J; Wilson JD; Yu L; Merlin JS; Murray-Krezan C
    Subst Use Addctn J; 2024 Jun; ():29767342241261562. PubMed ID: 38907678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Buprenorphine/naloxone versus methadone opioid rotation in patients with prescription opioid use disorder and chronic pain: study protocol for a randomized controlled trial.
    Ellerbroek H; van den Heuvel SAS; Dahan A; Timmerman H; Kramers C; Schellekens AFA
    Addict Sci Clin Pract; 2022 Sep; 17(1):47. PubMed ID: 36057608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Integrating the Management of Pain and Addiction via Collaborative Treatment (IMPACT) in Individuals With Chronic Pain and Opioid Use Disorder: Protocol for a Randomized Clinical Trial of a Digital Cognitive Behavioral Treatment.
    MacLean RR; Ankawi B; Driscoll MA; Gordon MA; Frankforter TL; Nich C; Szollosy SK; Loya JM; Brito L; Ribeiro MIP; Edmond SN; Becker WC; Martino S; Sofuoglu M; Heapy AA
    JMIR Res Protoc; 2024 Mar; 13():e54342. PubMed ID: 38506917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility of Web-Based Single-Session Empowered Relief in Patients With Chronic Pain Taking Methadone or Buprenorphine: Protocol for a Single-Arm Trial.
    Klein MR; Darnall BD; You DS
    JMIR Res Protoc; 2024 Jun; 13():e53784. PubMed ID: 38843513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans.
    Petrakis I; Springer SA; Davis C; Ralevski E; Gu L; Lew R; Hermos J; Nuite M; Gordon AJ; Kosten TR; Nunes EV; Rosenheck R; Saxon AJ; Swift R; Goldberg A; Ringer R; Ferguson R
    Addict Sci Clin Pract; 2022 Jan; 17(1):6. PubMed ID: 35101115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Video directly observed therapy intervention using a mobile health application among opioid use disorder patients receiving office-based buprenorphine treatment: protocol for a pilot randomized controlled trial.
    Schramm ZA; Leroux BG; Radick AC; Ventura AS; Klein JW; Samet JH; Saxon AJ; Kim TW; Tsui JI
    Addict Sci Clin Pract; 2020 Jul; 15(1):30. PubMed ID: 32736660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale and design of a multisite randomized clinical trial examining an integrated behavioral treatment for veterans with co-occurring chronic pain and opioid use disorder: The pain and opioids integrated treatment in veterans (POSITIVE) trial.
    Vowles KE; Witkiewitz K; Clarke E; Schmidt Z; Borsari B; Edwards KE; Korecki JR; Moniz-Lewis DI; Bondzie JA; Mullins C; Thoreson CI; Delacruz J; Wilkins CH; Nelson S; Delventura J; Henderson R; Katz A; Hua W; Watson E; Baxley C; Canlas BR; Pendleton T; Herbst E; Batki S
    Contemp Clin Trials; 2023 Mar; 126():107096. PubMed ID: 36693589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 "optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)".
    Shulman M; Weiss R; Rotrosen J; Novo P; Costello E; Nunes EV
    Addict Sci Clin Pract; 2021 Mar; 16(1):15. PubMed ID: 33676577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing rapid micro-induction and standard induction of buprenorphine/naloxone for treatment of opioid use disorder: protocol for an open-label, parallel-group, superiority, randomized controlled trial.
    Wong JSH; Nikoo M; Westenberg JN; Suen JG; Wong JYC; Krausz RM; Schütz CG; Vogel M; Sidhu JA; Moe J; Arishenkoff S; Griesdale D; Mathew N; Azar P
    Addict Sci Clin Pract; 2021 Feb; 16(1):11. PubMed ID: 33579359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and protocol of the Buprenorphine plus Outpatient Parenteral Antimicrobial Therapy (B-OPAT) study: a randomized clinical trial of integrated outpatient treatment of opioid use disorder and severe, injection-related infections.
    Fanucchi LC; Murphy SM; Surratt H; Kapadia SN; Walsh SL; Grubbs JA; Thornton AC; Nuzzo P; Lofwall MR
    Ther Adv Infect Dis; 2022; 9():20499361221108005. PubMed ID: 35847566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-Dose Buprenorphine Initiation for Hospitalized Patients With Chronic Pain and Opioid Use Disorder or Opioid Misuse: Protocol for an Open-Label, Parallel-Group, Effectiveness-Implementation Randomized Controlled Trial.
    Hayes BT; Sanchez Fat G; Torres-Lockhart K; Khalid L; Minami H; Ghiroli M; Hribar MB; Pacifico J; Bao Y; Rodgers CRR; Gabbay V; Starrels J; Fox AD
    Subst Use Addctn J; 2024 Jul; ():29767342241263221. PubMed ID: 39068540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stepped Care for Patients to Optimize Whole Recovery (SC-POWR): An Effectiveness Trial Evaluating a Stepped Care Model for Individuals With Opioid Use Disorder and Chronic Pain.
    Rossi R; Cutter CJ; Beitel M; Covelli M; Fiellin DA; Kerns RD; Vassilieva S; Olabisi D; Barry DT
    Subst Use Addctn J; 2024 Apr; ():29767342241245095. PubMed ID: 38606900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PRimary Care Opioid Use Disorders treatment (PROUD) trial protocol: a pragmatic, cluster-randomized implementation trial in primary care for opioid use disorder treatment.
    Campbell CI; Saxon AJ; Boudreau DM; Wartko PD; Bobb JF; Lee AK; Matthews AG; McCormack J; Liu DS; Addis M; Altschuler A; Samet JH; LaBelle CT; Arnsten J; Caldeiro RM; Borst DT; Stotts AL; Braciszewski JM; Szapocznik J; Bart G; Schwartz RP; McNeely J; Liebschutz JM; Tsui JI; Merrill JO; Glass JE; Lapham GT; Murphy SM; Weinstein ZM; Yarborough BJH; Bradley KA
    Addict Sci Clin Pract; 2021 Jan; 16(1):9. PubMed ID: 33517894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care.
    Tofighi B; Williams AR; Chemi C; Suhail-Sindhu S; Dickson V; Lee JD
    Subst Use Misuse; 2019; 54(14):2409-2419. PubMed ID: 31429351
    [No Abstract]   [Full Text] [Related]  

  • 15. The Community-Based Medication-First program for opioid use disorder: a hybrid implementation study protocol of a rapid access to buprenorphine program in Washington State.
    Banta-Green CJ; Owens MD; Williams JR; Sears JM; Floyd AS; Williams-Gilbert W; Kingston S
    Addict Sci Clin Pract; 2022 Jul; 17(1):34. PubMed ID: 35799210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of opioid use disorder treatment outcomes in patients receiving split daily versus once daily dosing of buprenorphine-naloxone.
    Borris JB; Dowd-Green C; Bowman LA; Nesbit SA; Fingerhood M; Stewart RW
    J Subst Use Addict Treat; 2024 Jan; 156():209209. PubMed ID: 37939905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Supervised dosing with a long-acting opioid medication in the management of opioid dependence.
    Saulle R; Vecchi S; Gowing L
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD011983. PubMed ID: 28447766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study design to evaluate a group-based therapy for support persons of adults on buprenorphine/naloxone.
    Osilla KC; Becker K; Ecola L; Hurley B; Manuel JK; Ober A; Paddock SM; Watkins KE
    Addict Sci Clin Pract; 2020 Jul; 15(1):25. PubMed ID: 32653029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Examining the benefit of a higher maintenance dose of extended-release buprenorphine in opioid-injecting participants treated for opioid use disorder.
    Greenwald MK; Wiest KL; Haight BR; Laffont CM; Zhao Y
    Harm Reduct J; 2023 Dec; 20(1):173. PubMed ID: 38042801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Collaborative care in the treatment of opioid use disorder and mental health conditions in primary care: A clinical study protocol.
    Harris RA; Mandell DS; Kampman KM; Bao Y; Campbell K; Cidav Z; Coviello DM; French R; Livesey C; Lowenstein M; Lynch KG; McKay JR; Oslin DW; Wolk CB; Bogner HR
    Contemp Clin Trials; 2021 Apr; 103():106325. PubMed ID: 33631356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.